Agents to Treat Erectile Dysfunction, cGMP-Type

The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil

The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil

The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil

These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal

These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal

These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal While formulated primarily as first-line oral therapies for erectile dysfunction, agents within this broader mechanistic family are also utilized to treat pulmonary arterial hypertension and lower urinary tract symptoms secondary to benign prostatic hyperplasi...

While formulated primarily as first-line oral therapies for erectile dysfunction, agents within this broader mechanistic family are also utilized to treat pulmonary arterial hypertension and lower urinary tract symptoms secondary to benign prostatic hyperplasia